A mitochondrial fission protein rose in high-glucose pregnancy — in placental cells and rats

Edited by Samael A. Tejada, Founder & Editor-in-Chief

A blood marker for gestational diabetes risk would be valuable. This study finds a mitochondrial protein behaving like one — in a dish and in rats, which is exactly where candidate markers start, and where most of them stop.

What exactly was measured?

The discovery arm was proteomics: human BeWo trophoblast cells — a standard placental cell model — syncytialised under high-glucose (25 millimolar) conditions and compared with undifferentiated normoglycaemic (5 millimolar) controls, with three replicates per group. Of 3,528 protein groups quantified, 388 were differentially abundant and 24 passed strict multiple-testing correction. MFF increased 4.5-fold (q = 0.040); DRP1, the GTPase MFF recruits, did not change. Adding VEGF did not reproduce the signature (MFF 0.91-fold, p = 0.71), which argues the signal tracks the glucose condition rather than a generic growth-factor response.

Did the signal reach the blood?

That is the finding that elevates this from a cell-culture observation. Targeted ELISA assays confirmed MFF was 48% higher in lysates of the high-glucose cells, and — in streptozotocin-treated hyperglycaemic pregnant rats — 41% higher in maternal serum on gestational day 7 than in controls (both p < 0.001, n=3 per group). A mitochondrial inner-workings protein appearing in maternal blood at higher levels under hyperglycaemia is the pattern a screening biomarker would need. It is also, at this stage, three rats per group.

What would it take for this to become a test?

Human validation, in order: first, does MFF differ in blood from pregnant women with and without gestational diabetes, in adequately sized cohorts? Second, does it add anything over the glucose testing already used — earlier, cheaper, or more predictive? Third, the confound the authors themselves flag: in the cell experiments, glucose concentration and syncytial differentiation changed together, so part of the signature may belong to differentiation rather than glucose. None of that diminishes the observation; it defines the distance between a candidate and a test. Readers will see 'mitochondrial biomarker for pregnancy diabetes' headlines built on far less — this one at least shows its working.

Where the evidence stands

• Established: MFF is the outer-membrane receptor that recruits DRP1 to execute mitochondrial fission; mitochondrial dynamics are altered in diabetic tissues including placenta; gestational diabetes is currently diagnosed by glucose testing.
• Preliminary: MFF as a hyperglycaemia-associated signal: one proteomics study (Cells, 2026) in a placental cell line (n=3 per group) with ELISA confirmation in cells and in hyperglycaemic pregnant rats. Association only; glucose and differentiation were co-varied in the cell model.
• Absent: Human evidence — MFF has not been measured as a gestational-diabetes biomarker in pregnant women, and no predictive performance has been established.